re: pyc - investor presentation - july 2012, page-4

re: pyc - investor presentation - july 2012 If you look on slide 40 beside "Peptide drugs against intractable extracellular targets" it has under "In-House Activities & Partnerships"...

Developing new screening assays against high-value GPCRs

I contacted Nick Woolf to ask if he could give me a short description of what GPCR targeted drugs are and Phylogica's role with them are and here's his reply....

G protein-coupled receptor

GPCR-targeted drugs are one the largest drug classes. These receptors are key regulators of cell biology. Some of the high-value GPCRs have been challenging to hit with conventional small molecule or antibody drugs because of their complex biological shapes. We can tackle these ones with our Phylomers.

http://en.wikipedia.org/wiki/G_protein-coupled_receptor

Number of deal discussions to date in this space = 8.

Phylogica just need one of their Phylomers in the hands of one of their partners, or indeed in their own hands, to show proof of concept (even preclinical) against a high-value challenging target. Then they will be taken out.

Regards,
Tony